<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28923989</article-id><article-id pub-id-type="pmc">5634257</article-id><article-id pub-id-type="doi">10.1161/JAHA.117.005840</article-id><article-id pub-id-type="publisher-id">JAH32531</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Coronary Heart Disease</subject></subj-group></subj-group></article-categories><title-group><article-title>Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long&#x02010;Term Follow&#x02010;Up After Acute Coronary Syndromes</article-title><alt-title alt-title-type="left-running-head">Fanaroff et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah32531-cr-0001" contrib-type="author" corresp="yes"><name><surname>Fanaroff</surname><given-names>Alexander C.</given-names></name><degrees>MD</degrees><address><email>alexander.fanaroff@duke.edu</email></address><xref ref-type="aff" rid="jah32531-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32531-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32531-cr-0002" contrib-type="author"><name><surname>Roe</surname><given-names>Matthew T.</given-names></name><degrees>MD, MHS</degrees><xref ref-type="aff" rid="jah32531-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32531-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32531-cr-0003" contrib-type="author"><name><surname>Clare</surname><given-names>Robert M.</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="jah32531-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32531-cr-0004" contrib-type="author"><name><surname>Lokhnygina</surname><given-names>Yuliya</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah32531-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32531-cr-0005" contrib-type="author"><name><surname>Navar</surname><given-names>Ann Marie</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32531-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32531-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32531-cr-0006" contrib-type="author"><name><surname>Giugliano</surname><given-names>Robert P.</given-names></name><degrees>MD, SM</degrees><xref ref-type="aff" rid="jah32531-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32531-cr-0007" contrib-type="author"><name><surname>Wiviott</surname><given-names>Stephen D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32531-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32531-cr-0008" contrib-type="author"><name><surname>Tershakovec</surname><given-names>Andrew M.</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="jah32531-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah32531-cr-0009" contrib-type="author"><name><surname>Braunwald</surname><given-names>Eugene</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32531-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32531-cr-0010" contrib-type="author"><name><surname>Blazing</surname><given-names>Michael A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32531-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32531-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="jah32531-aff-0001">
<label><sup>1</sup></label>
<institution>Duke Clinical Research Institute</institution>
<named-content content-type="city">Durham</named-content>
<named-content content-type="country-part">NC</named-content>
</aff><aff id="jah32531-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Division of Cardiology</named-content>
<institution>Duke University</institution>
<named-content content-type="city">Durham</named-content>
<named-content content-type="country-part">NC</named-content>
</aff><aff id="jah32531-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Thrombolysis in Myocardial Infarction (TIMI) Study Group</named-content>
<institution>Brigham and Women's Hospital and Harvard Medical School</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">MA</named-content>
</aff><aff id="jah32531-aff-0004">
<label><sup>4</sup></label>
<institution>Merck &#x00026; Co. Inc.</institution>
<named-content content-type="city">Kenilworth</named-content>
<named-content content-type="country-part">NJ</named-content>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Alexander C. Fanaroff, MD, Duke Clinical Research Institute, 2400 Pratt St, Durham, NC. E&#x02010;mail: <email>alexander.fanaroff@duke.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2017</year></pub-date><volume>6</volume><issue>9</issue><issue-id pub-id-type="doi">10.1002/jah3.2017.6.issue-9</issue-id><elocation-id>e005840</elocation-id><history><date date-type="received"><day>01</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>25</day><month>7</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors and Merck Sharp &#x00026; Dohme Corp. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-6-e005840.pdf"/><abstract id="jah32531-abs-0001"><sec id="jah32531-sec-0001"><title>Background</title><p>Understanding the relative risk of cardiovascular versus noncardiovascular death is important for designing clinical trials. These risks may differ depending on patient age, sex, and type of acute coronary syndrome (<styled-content style="fixed-case">ACS</styled-content>).</p></sec><sec id="jah32531-sec-0002"><title>Methods and Results</title><p>
<styled-content style="fixed-case">IMPROVE</styled-content>&#x02010;<styled-content style="fixed-case">IT</styled-content> (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) was a randomized controlled trial of simvastatin plus either ezetimibe or placebo following stabilized <styled-content style="fixed-case">ACS</styled-content>. Cause of death was adjudicated by an independent committee. We compared the cumulative incidence of cardiovascular and noncardiovascular death for patients with unstable angina/non&#x02010;<styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation myocardial infarction (<styled-content style="fixed-case">UA</styled-content>/<styled-content style="fixed-case">NSTEMI</styled-content>) and <styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation myocardial infarction (<styled-content style="fixed-case">STEMI</styled-content>), in those &#x0003c;65 and &#x02265;65&#x000a0;years old, and males and females, over 7&#x000a0;years of follow&#x02010;up. Of 18&#x000a0;131 patients, the presenting event was <styled-content style="fixed-case">STEMI</styled-content> for 5190 (29%) and <styled-content style="fixed-case">UA</styled-content>/<styled-content style="fixed-case">NSTEMI</styled-content> for 12&#x000a0;941 (71%); 10&#x000a0;173 (56%) patients were &#x0003c;65 years old and 7971 (44%) were &#x02265;65&#x000a0;years old at presentation. <styled-content style="fixed-case">UA</styled-content>/<styled-content style="fixed-case">NSTEMI</styled-content> patients were older than <styled-content style="fixed-case">STEMI</styled-content> patients, with more cardiovascular and noncardiovascular risk factors. In <styled-content style="fixed-case">STEMI</styled-content> patients, the cumulative incidence of cardiovascular death was higher for &#x0223c;4&#x000a0;years following the index event, after which noncardiovascular death predominated. In <styled-content style="fixed-case">UA</styled-content>/<styled-content style="fixed-case">NSTEMI</styled-content> patients, the cumulative incidence of cardiovascular death remained higher than noncardiovascular death over the full follow&#x02010;up period. Patients &#x02265;65 years old and &#x0003c;65&#x000a0;years old had a higher incidence of cardiovascular death than noncardiovascular death over the entirety of follow&#x02010;up. Female patients had a higher incidence of cardiovascular death than noncardiovascular death for &#x0223c;6&#x000a0;years following the index event; male patients had a higher incidence of cardiovascular death than noncardiovascular death over the entirety of follow&#x02010;up.</p></sec><sec id="jah32531-sec-0003"><title>Conclusions</title><p>Among post&#x02010;<styled-content style="fixed-case">ACS</styled-content> patients enrolled in a long&#x02010;term clinical trial, the relative incidence of cardiovascular and noncardiovascular death differed based on type of <styled-content style="fixed-case">ACS</styled-content> presentation and sex, but not age. These findings further delineate long&#x02010;term prognosis after <styled-content style="fixed-case">ACS</styled-content> and should inform the design of future cardiovascular outcomes trials.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah32531-kwd-0001">acute coronary syndrome</kwd><kwd id="jah32531-kwd-0002">clinical trial</kwd><kwd id="jah32531-kwd-0003">death</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Acute Coronary Syndromes</kwd></kwd-group><funding-group><award-group><funding-source>Merck &#x00026; Co., Inc</funding-source></award-group><award-group><funding-source>NIH</funding-source><award-id>5T32HL069749-13</award-id></award-group><award-group><funding-source>American Heart Association</funding-source><award-id>17FTF33661087</award-id></award-group><award-group><funding-source>NHLBI</funding-source><award-id>K01HL133416</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="10"/><word-count count="7277"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah32531</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.0 mode:remove_FC converted:26.09.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah32531-cit-1001">(<source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e005840</elocation-id> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.117.005840">10.1161/JAHA.117.005840</ext-link>.)<pub-id pub-id-type="pmid">28923989</pub-id></mixed-citation>
</p></notes></front><body><p>
<boxed-text position="anchor" content-type="box" id="jah32531-blkfxd-0001" orientation="portrait"><sec id="jah32531-sec-0005"><title>Clinical Perspective</title><sec id="jah32531-sec-0006"><title>What Is New?</title><p>
<list list-type="bullet" id="jah32531-list-0001"><list-item><p>This analysis of IMPROVE&#x02010;IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) demonstrated that the relative incidence of cardiovascular and noncardiovascular death differed based on type of acute coronary syndrome presentation, but not age.</p></list-item><list-item><p>In patients with <styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation myocardial infarction, the cumulative incidence of cardiovascular death was higher for 4&#x000a0;years following the index event, after which noncardiovascular death predominated; however, patients with non&#x02010;<styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation myocardial infarction or unstable angina had a higher incidence of cardiovascular death over the full follow&#x02010;up period.</p></list-item><list-item><p>Patients &#x02265;65&#x000a0;years old and &#x0003c;65&#x000a0;years old had a higher incidence of cardiovascular death than noncardiovascular death over the entirety of follow&#x02010;up.</p></list-item></list>
</p></sec><sec id="jah32531-sec-0007"><title>What Are the Clinical Implications?</title><p>
<list list-type="bullet" id="jah32531-list-0002"><list-item><p>Patients with unstable angina or non&#x02010;<styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation myocardial infarction remain at higher risk for cardiovascular death than noncardiovascular death over long&#x02010;term follow&#x02010;up, and their comorbidities should be targeted appropriately.</p></list-item><list-item><p>The long&#x02010;term incidence of cardiovascular death following admission for unstable angina or non&#x02010;<styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation myocardial infarction remains high, despite advancements in pharmacotherapy and invasive management.</p></list-item></list>
</p></sec></sec></boxed-text>
</p><sec id="jah32531-sec-0008"><title>Introduction</title><p>Patients with unstable angina (UA) and non&#x02010;ST&#x02010;segment elevation myocardial infarction (NSTEMI) differ from those with ST&#x02010;segment elevation myocardial infarction (STEMI) in important ways; as a group, they are older and more likely to have both cardiovascular and other comorbidities, including diabetes mellitus, chronic lung disease, and chronic kidney disease.<xref rid="jah32531-bib-0001" ref-type="ref">1</xref>, <xref rid="jah32531-bib-0002" ref-type="ref">2</xref>, <xref rid="jah32531-bib-0003" ref-type="ref">3</xref>, <xref rid="jah32531-bib-0004" ref-type="ref">4</xref>, <xref rid="jah32531-bib-0005" ref-type="ref">5</xref> Epidemiologic studies and clinical trials have mostly demonstrated that all&#x02010;cause mortality is greater for patients with STEMI than for those with UA/NSTEMI over the first 2 to 3&#x000a0;months after the event, but over long&#x02010;term follow&#x02010;up, all&#x02010;cause mortality is higher for patients with UA/NSTEMI compared with STEMI and for older patients compared with younger patients.<xref rid="jah32531-bib-0006" ref-type="ref">6</xref>, <xref rid="jah32531-bib-0007" ref-type="ref">7</xref>, <xref rid="jah32531-bib-0008" ref-type="ref">8</xref>, <xref rid="jah32531-bib-0009" ref-type="ref">9</xref>, <xref rid="jah32531-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32531-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32531-bib-0012" ref-type="ref">12</xref>, <xref rid="jah32531-bib-0013" ref-type="ref">13</xref>, <xref rid="jah32531-bib-0014" ref-type="ref">14</xref>, <xref rid="jah32531-bib-0015" ref-type="ref">15</xref>, <xref rid="jah32531-bib-0016" ref-type="ref">16</xref> However, these studies were unable to reliably capture cause of death and, as such, are unable to determine the contributions of cardiovascular and noncardiovascular mortality to overall mortality in post&#x02013;acute coronary syndrome (ACS) patients.</p><p>The relative incidence of cardiovascular and noncardiovascular death is of particular interest in the design and interpretation of cardiovascular clinical trials. Failure to account for the competing risk of noncardiovascular death can lead to overestimates of event rates observed, and noncardiovascular death rates affect sample size as patients are effectively &#x0201c;censored&#x0201d; at the time of death.<xref rid="jah32531-bib-0017" ref-type="ref">17</xref>, <xref rid="jah32531-bib-0018" ref-type="ref">18</xref> The relative likelihood of cardiovascular versus noncardiovascular death after initial presentation with ACS is likely to change over time and to differ among patients who present with STEMI and UA/NSTEMI, given differences in baseline characteristics, but this has not been well defined over a prolonged follow&#x02010;up period. Further delineation of the long&#x02010;term frequencies of cardiovascular versus noncardiovascular death following ACS may inform the design and conduct of future cardiovascular outcomes trials that commonly incorporate cardiovascular death into the composite primary outcome and may help patients and physicians prioritize multiple competing comorbidities.</p><p>The strict adjudication of end points and long duration of follow&#x02010;up of contemporary post&#x02010;ACS patients in the IMPROVE&#x02010;IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) allow for an in&#x02010;depth exploration of the relative incidence of cardiovascular and noncardiovascular mortality in a large cohort of patients with ACS. Specifically, the goals of this analysis were to (1) compare the cumulative incidence of cardiovascular and noncardiovascular death over time in patients after ACS, and (2) determine whether the relative contributions of cardiovascular and noncardiovascular mortality varied by presenting diagnosis or patient age.</p></sec><sec id="jah32531-sec-0009"><title>Methods</title><p>The IMPROVE&#x02010;IT trial design and primary results have been previously published.<xref rid="jah32531-bib-0019" ref-type="ref">19</xref>, <xref rid="jah32531-bib-0020" ref-type="ref">20</xref>, <xref rid="jah32531-bib-0021" ref-type="ref">21</xref> Briefly, IMPROVE&#x02010;IT was a randomized, double&#x02010;blind, placebo&#x02010;controlled clinical trial testing the efficacy and safety of ezetimibe compared with placebo on a background of simvastatin therapy for the prevention of cardiovascular events in patients stabilized after hospitalization for ACS. Patients were enrolled within 10&#x000a0;days of hospitalization for ACS, and received simvastatin 40&#x000a0;mg daily with either ezetimibe or matching placebo. All patients with acute MI &#x02265;50&#x000a0;years of age; patients with anterior STEMI of any age; and patients with UA who were &#x02265;50&#x000a0;years old and had either diabetes mellitus, prior myocardial infarction (MI), a history of peripheral arterial disease or cerebrovascular disease, coronary artery bypass grafting within at least 3&#x000a0;years, or known multivessel coronary artery disease were eligible for inclusion. All patients were required to be hospitalized with symptoms of acute cardiac ischemia. Key exclusion criteria included planned coronary artery bypass grafting surgery, creatinine clearance &#x0003c;30&#x000a0;mL/min, active liver disease, or ongoing treatment with statin therapy with greater potency than simvastatin 40&#x000a0;mg daily.</p><p>The trial was designed so that the minimum follow&#x02010;up for each patient was 30&#x000a0;months; because of prolonged enrollment, the median follow&#x02010;up was 6&#x000a0;years. The trial began enrolling patients on October 26, 2005; because of high enrollment of patients with STEMI in the first phase of the trial, and concern that the lower long&#x02010;term risk of these patients would require lengthening of follow&#x02010;up, enrollment of these patients was phased out beginning in September 2007 and was nearly complete by April 2008.<xref rid="jah32531-bib-0021" ref-type="ref">21</xref> Total enrollment was completed on July 8, 2010. Though 42% of patients discontinued the study drug by 6&#x000a0;years, an average of 7% per year, only 653 patients (3.5%) had unknown vital status at the conclusion of the trial. This analysis includes all randomized patients except those with missing MI type (n=13).</p><sec id="jah32531-sec-0010"><title>Outcomes and Key Covariates</title><p>The co&#x02010;primary outcomes for this analysis were cardiovascular and noncardiovascular death. Cardiovascular death was classified as death caused by coronary heart disease (fatal MI, sudden death, nonsudden cardiac death, unwitnessed death, or procedural death), other atherosclerotic disease (cerebrovascular disease and other), and other nonatherosclerotic cardiovascular disease. Noncardiovascular death was classified as death caused by diabetes mellitus, malignancy, renal disease, accident, suicide, and other. Clinical end points, including cause of death, were adjudicated using standardized definitions by a clinical events committee blinded to treatment assignment.</p><p>STEMI was defined as symptoms of cardiac ischemia, persistent ST&#x02010;segment elevation &#x02265;0.1&#x000a0;mV in at least 2 contiguous ECG leads, and elevation in troponin I, troponin T, or creatine kinase MB fraction above the upper limit of normal. NSTEMI was defined as symptoms of cardiac ischemia plus elevation in troponin I, troponin T, or creatine kinase MB fraction above the upper limit of normal without persistent ST&#x02010;segment elevation. Any other patient meeting inclusion criteria for the study was diagnosed with UA.</p></sec><sec id="jah32531-sec-0011"><title>Statistical Analysis</title><p>Baseline characteristics stratified by diagnosis (STEMI and UA/NSTEMI), age (&#x0003c;65 and &#x02265;65&#x000a0;years old), and sex (male and female) were reported as frequencies with percentages for categorical variables and as medians (25th, 75th percentiles) for continuous variables. Categorical variables were compared using &#x003c7;<sup>2</sup> tests, and continuous variables were compared using analysis of variance; where distributional assumptions were violated, we used Fisher exact and Kruskal&#x02013;Wallis tests, respectively.</p><p>We evaluated the cumulative incidence of cardiovascular and noncardiovascular death over 7&#x000a0;years of follow&#x02010;up by presenting diagnosis (UA/NSTEMI versus STEMI), age (&#x0003c;65 and &#x02265;65&#x000a0;years old), and sex (female versus male); we also evaluated the cumulative incidence of noncardiovascular death and the trial's primary end point (cardiovascular death, nonfatal MI, nonfatal stroke, UA requiring hospital admission, or coronary revascularization occurring at least 30&#x000a0;days after randomization) by presenting diagnosis and age. Since these results were similar for patients randomized to simvastatin and those randomized to simvastatin plus ezetimibe, pooled data are presented. Scaled Schoenfeld residuals were used to evaluate the proportional hazards assumption for STEMI versus UA/NSTEMI and for age &#x0003c;65 versus &#x02265;65&#x000a0;years old for the outcomes of cardiovascular and noncardiovascular death over the 7&#x02010;year follow&#x02010;up. Because proportional hazards were not met for the comparison of cardiovascular death in patients with STEMI versus UA/NSTEMI, we produced a curve depicting the estimated hazard ratio of cardiovascular death for patients with STEMI versus UA/NSTEMI at any given point over the follow&#x02010;up interval using the methods described by Lunn and McNeil.<xref rid="jah32531-bib-0022" ref-type="ref">22</xref> We also tested whether hazard ratios for STEMI versus UA/NSTEMI and age &#x0003c;65 versus &#x02265;65&#x000a0;years old were different for cardiovascular as compared with noncardiovascular death.<xref rid="jah32531-bib-0022" ref-type="ref">22</xref>
</p><p>Since the trial stopped enrollment of patients with STEMI earlier than those with UA/NSTEMI, median duration of follow&#x02010;up was different for patients with STEMI compared with those with UA/NSTEMI. Therefore, as a sensitivity analysis, we repeated the above analyses including only patients enrolled from October 26, 2005 through April 1, 2008, the time period when the trial enrolled both STEMI and UA/NSTEMI patients.</p><p>To account for the fact that the trial inclusion criteria for patients with UA enriched for patients with more severe vascular disease, we performed a second sensitivity analysis that attempted to minimize the effect of the trial inclusion criteria. For this analysis, we included only patients &#x02265;50&#x000a0;years old with elevated cardiac biomarkers; in effect, this analysis compared patients &#x02265;50&#x000a0;years old with STEMI to those with NSTEMI, independent of enrichment factors.</p><p>All participants in IMPROVE&#x02010;IT provided written informed consent to participate. The investigators had full access to all of the data. The Duke Clinical Research Institute performed all analyses using SAS software, version 9.3.</p></sec></sec><sec id="jah32531-sec-0012"><title>Results</title><sec id="jah32531-sec-0013"><title>Baseline Clinical Characteristics</title><p>Of 18&#x000a0;144 patients enrolled in IMPROVE&#x02010;IT, 18&#x000a0;131 had data for ACS type, and all had data for age. The qualifying ACS event was STEMI for 5190 patients (28.6%), and UA/NSTEMI for 12&#x000a0;941 (71.4%), of whom 8555 had NSTEMI and 4386 had UA. Compared with patients with STEMI, patients with UA/NSTEMI were older and had a higher burden of risk factors, but were less likely to have undergone percutaneous coronary intervention (PCI) during hospitalization for their index event and to have been discharged on guideline&#x02010;directed secondary prevention medications (<italic>P</italic>&#x0003c;0.001 for all comparisons, <xref rid="jah32531-tbl-0001" ref-type="table-wrap">Table</xref>). Limiting this analysis to the time period during which both STEMI and UA/NSTEMI were being enrolled resulted in 5033 presenting with STEMI and 6099 with UA/NSTEMI.</p><table-wrap id="jah32531-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Characteristics by ACS Type and Age</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" rowspan="2" valign="top" colspan="1">Overall (N=18&#x000a0;144)</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">ACS Type</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Age</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">STEMI (N=5190)</th><th align="left" valign="top" rowspan="1" colspan="1">UA/NSTEMI (N=12&#x000a0;941)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th><th align="left" valign="top" rowspan="1" colspan="1">&#x0003c;65&#x000a0;Y (N=10&#x000a0;173)</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265; 65&#x000a0;Y (N=7971)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" colspan="8" rowspan="1">Demographic characteristics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">63 (56, 71)</td><td align="left" rowspan="1" colspan="1">60 (54, 68)</td><td align="left" rowspan="1" colspan="1">64 (57, 72)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">57 (53, 61)</td><td align="left" rowspan="1" colspan="1">72 (68, 77)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male sex</td><td align="left" rowspan="1" colspan="1">13&#x000a0;728 (75.7%)</td><td align="left" rowspan="1" colspan="1">4154 (80.0%)</td><td align="left" rowspan="1" colspan="1">9566 (73.9%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">8105 (79.7%)</td><td align="left" rowspan="1" colspan="1">5623 (70.5%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">15&#x000a0;202 (83.8%)</td><td align="left" rowspan="1" colspan="1">4458 (85.9%)</td><td align="left" rowspan="1" colspan="1">10&#x000a0;734 (82.9%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">8316 (81.8%)</td><td align="left" rowspan="1" colspan="1">6886 (86.4%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">28 (25, 31)</td><td align="left" rowspan="1" colspan="1">27 (25, 30)</td><td align="left" rowspan="1" colspan="1">28 (25, 31)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">28 (25, 32)</td><td align="left" rowspan="1" colspan="1">27 (25, 30)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="8" rowspan="1">Prior medical history</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of hypertension</td><td align="left" rowspan="1" colspan="1">11&#x000a0;137 (61.4%)</td><td align="left" rowspan="1" colspan="1">2499 (48.2%)</td><td align="left" rowspan="1" colspan="1">8636 (66.7%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">5622 (55.3%)</td><td align="left" rowspan="1" colspan="1">5515 (69.2%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of diabetes mellitus</td><td align="left" rowspan="1" colspan="1">4933 (27.2%)</td><td align="left" rowspan="1" colspan="1">1013 (19.5%)</td><td align="left" rowspan="1" colspan="1">3917 (30.3%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">2506 (24.6%)</td><td align="left" rowspan="1" colspan="1">2427 (30.5%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior CHF</td><td align="left" rowspan="1" colspan="1">790 (4.4%)</td><td align="left" rowspan="1" colspan="1">70 (1.3%)</td><td align="left" rowspan="1" colspan="1">720 (5.6%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">296 (2.9%)</td><td align="left" rowspan="1" colspan="1">494 (6.2%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior atrial fibrillation</td><td align="left" rowspan="1" colspan="1">948 (5.2%)</td><td align="left" rowspan="1" colspan="1">119 (2.3%)</td><td align="left" rowspan="1" colspan="1">829 (6.4%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">250 (2.5%)</td><td align="left" rowspan="1" colspan="1">698 (8.8%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous PAD</td><td align="left" rowspan="1" colspan="1">1005 (5.5%)</td><td align="left" rowspan="1" colspan="1">156 (3.0%)</td><td align="left" rowspan="1" colspan="1">848 (6.6%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">391 (3.8%)</td><td align="left" rowspan="1" colspan="1">614 (7.7%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior PCI</td><td align="left" rowspan="1" colspan="1">3562 (19.6%)</td><td align="left" rowspan="1" colspan="1">453 (8.7%)</td><td align="left" rowspan="1" colspan="1">3106 (24.0%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1786 (17.6%)</td><td align="left" rowspan="1" colspan="1">1776 (22.3%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior CABG</td><td align="left" rowspan="1" colspan="1">1684 (9.3%)</td><td align="left" rowspan="1" colspan="1">96 (1.9%)</td><td align="left" rowspan="1" colspan="1">1588 (12.3%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">611 (6.0%)</td><td align="left" rowspan="1" colspan="1">1073 (13.5%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of angina</td><td align="left" rowspan="1" colspan="1">7449 (41.1%)</td><td align="left" rowspan="1" colspan="1">1011 (19.5%)</td><td align="left" rowspan="1" colspan="1">6437 (49.7%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">3658 (36.0%)</td><td align="left" rowspan="1" colspan="1">3791 (47.6%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior multivessel CAD</td><td align="left" rowspan="1" colspan="1">2706 (15.4%)</td><td align="left" rowspan="1" colspan="1">217 (4.3%)</td><td align="left" rowspan="1" colspan="1">2488 (20.0%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1177 (11.9%)</td><td align="left" rowspan="1" colspan="1">1529 (20.0%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous MI</td><td align="left" rowspan="1" colspan="1">3806 (21.0%)</td><td align="left" rowspan="1" colspan="1">487 (9.4%)</td><td align="left" rowspan="1" colspan="1">3316 (25.6%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1864 (18.3%)</td><td align="left" rowspan="1" colspan="1">1942 (24.4%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of stroke</td><td align="left" rowspan="1" colspan="1">682 (3.8%)</td><td align="left" rowspan="1" colspan="1">104 (2.0%)</td><td align="left" rowspan="1" colspan="1">578 (4.5%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">254 (2.5%)</td><td align="left" rowspan="1" colspan="1">428 (5.4%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current smoker</td><td align="left" rowspan="1" colspan="1">5978 (33.0%)</td><td align="left" rowspan="1" colspan="1">2338 (45.1%)</td><td align="left" rowspan="1" colspan="1">12&#x000a0;939 (28.1%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">4614 (45.4%)</td><td align="left" rowspan="1" colspan="1">1364 (17.1%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="8" rowspan="1">Details of qualifying event</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">STEMI</td><td align="left" rowspan="1" colspan="1">5190 (28.6%)</td><td align="left" rowspan="1" colspan="1">5190 (100.0%)</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">3432 (33.8%)</td><td align="left" rowspan="1" colspan="1">1758 (22.1%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">NSTEMI</td><td align="left" rowspan="1" colspan="1">8555 (47.2)</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">8555 (66.1%)</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">4516 (44.4%)</td><td align="left" rowspan="1" colspan="1">4039 (50.7%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">UA</td><td align="left" rowspan="1" colspan="1">4386 (24.2%)</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">4386 (33.9%)</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">2217 (21.8%)</td><td align="left" rowspan="1" colspan="1">2169 (27.2%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Killip class</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">13&#x000a0;077 (72.3%)</td><td align="left" rowspan="1" colspan="1">3737 (72.0%)</td><td align="left" rowspan="1" colspan="1">9338 (72.4%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7434 (73.3%)</td><td align="left" rowspan="1" colspan="1">5643 (71.0%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1114 (6.2%)</td><td align="left" rowspan="1" colspan="1">348 (6.7%)</td><td align="left" rowspan="1" colspan="1">766 (5.9%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">494 (4.9%)</td><td align="left" rowspan="1" colspan="1">620 (7.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">301 (1.7%)</td><td align="left" rowspan="1" colspan="1">71 (1.4%)</td><td align="left" rowspan="1" colspan="1">230 (1.8%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">132 (1.3%)</td><td align="left" rowspan="1" colspan="1">169 (2.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">126 (0.4%)</td><td align="left" rowspan="1" colspan="1">62 (1.2%)</td><td align="left" rowspan="1" colspan="1">64 (0.5%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">67 (0.7%)</td><td align="left" rowspan="1" colspan="1">59 (0.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">3474 (19.2%</td><td align="left" rowspan="1" colspan="1">972 (18.7%)</td><td align="left" rowspan="1" colspan="1">2501 (19.4%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2014 (19.9%)</td><td align="left" rowspan="1" colspan="1">1460 (18.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Creatinine clearance</td><td align="left" rowspan="1" colspan="1">85 (66, 107)</td><td align="left" rowspan="1" colspan="1">88 (69, 110)</td><td align="left" rowspan="1" colspan="1">83 (64, 106)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">99 (81, 120)</td><td align="left" rowspan="1" colspan="1">68 (55, 84)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="8" rowspan="1">Treatment for qualifying event</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PCI during index hospitalization</td><td align="left" rowspan="1" colspan="1">12&#x000a0;641 (69.7%)</td><td align="left" rowspan="1" colspan="1">4633 (89.3%)</td><td align="left" rowspan="1" colspan="1">8007 (61.9%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">7447 (73.2%)</td><td align="left" rowspan="1" colspan="1">5194 (65.2%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CABG within 30&#x000a0;days of randomization</td><td align="left" rowspan="1" colspan="1">167 (0.9%)</td><td align="left" rowspan="1" colspan="1">28 (0.5%)</td><td align="left" rowspan="1" colspan="1">139 (1.1%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">81 (0.8%)</td><td align="left" rowspan="1" colspan="1">86 (1.1%)</td><td align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" colspan="8" rowspan="1">Concomitant medications at randomization</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td><td align="left" rowspan="1" colspan="1">17&#x000a0;898 (98.7%)</td><td align="left" rowspan="1" colspan="1">5161 (99.4%)</td><td align="left" rowspan="1" colspan="1">12&#x000a0;733 (98.4%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">10&#x000a0;069 (99.0%)</td><td align="left" rowspan="1" colspan="1">7829 (98.3%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x003b2;&#x02010;Blocker</td><td align="left" rowspan="1" colspan="1">16&#x000a0;672 (91.9%)</td><td align="left" rowspan="1" colspan="1">4944 (95.3%)</td><td align="left" rowspan="1" colspan="1">11&#x000a0;724 (90.6%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">9454 (93.0%)</td><td align="left" rowspan="1" colspan="1">7218 (90.6%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">P2Y<sub>12</sub> inhibitor</td><td align="left" rowspan="1" colspan="1">16&#x000a0;455 (90.8%)</td><td align="left" rowspan="1" colspan="1">4963 (95.7%)</td><td align="left" rowspan="1" colspan="1">11&#x000a0;490 (88.8%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">9328 (91.8%)</td><td align="left" rowspan="1" colspan="1">7127 (89.5%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACE inhibitor</td><td align="left" rowspan="1" colspan="1">12&#x000a0;743 (70.3%)</td><td align="left" rowspan="1" colspan="1">4051 (78.1%)</td><td align="left" rowspan="1" colspan="1">8690 (67.2%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">7264 (71.5%)</td><td align="left" rowspan="1" colspan="1">5479 (68.8%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nitrates</td><td align="left" rowspan="1" colspan="1">13&#x000a0;418 (74.0%)</td><td align="left" rowspan="1" colspan="1">3893 (75.1%)</td><td align="left" rowspan="1" colspan="1">9524 (73.6%)</td><td align="left" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1">7524 (74.0%)</td><td align="left" rowspan="1" colspan="1">5894 (74.0%)</td><td align="left" rowspan="1" colspan="1">0.95</td></tr></tbody></table><table-wrap-foot><fn id="jah32531-note-0002"><p>Continuous data presented as median (25th, 75th percentile); categorical data presented as count (percentage). ACE indicates angiotensin&#x02010;converting enzyme; ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; MI, myocardial infarction; NSTEMI, non&#x02010;STEMI; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; STEMI, ST&#x02010;segment elevation myocardial infarction; UA, unstable angina.</p></fn></table-wrap-foot></table-wrap><p>A total of 10&#x000a0;173 patients were &#x0003c;65&#x000a0;years old, and 7971 were &#x02265;65&#x000a0;years old. Compared with younger patients, older patients more often presented with UA/NSTEMI and had a higher burden of cardiac risk factors (<italic>P</italic>&#x0003c;0.001 for all comparisons). They had less frequently undergone PCI during hospitalization for their index event, but were taking guideline&#x02010;directed medical therapy at a similar rate to younger patients. Overall, 13&#x000a0;728 patients were male, compared with 4416 patients who were female. Compared with male patients, female patients were older and had a higher incidence of hypertension and diabetes mellitus, but a lower incidence of coronary artery bypass grafting and multivessel coronary artery disease. Their index event was less likely to be a STEMI, and they were less likely to have undergone PCI for this index event than male patients (Table&#x000a0;<xref rid="jah32531-sup-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="jah32531-sec-0014"><title>Cumulative Incidence of Cardiovascular Versus Noncardiovascular Death by ACS Type</title><p>Among patients with UA/NSTEMI, 842 patients (7&#x02010;year cumulative incidence 7.7%, 95% confidence interval [CI], 7.2&#x02013;8.3%) died of cardiovascular causes over the 7&#x02010;year follow&#x02010;up and 730 (7.0%, 95% CI, 6.5&#x02013;7.5%) died of noncardiovascular causes. For patients with STEMI, 232 (4.4%, 95% CI, 3.9&#x02013;5.0%) died of cardiovascular causes and 275 (5.2%, 95% CI, 4.6&#x02013;5.8%) died of noncardiovascular causes. The majority of cardiovascular deaths in both groups were caused by coronary heart disease; specific causes of death can be found in Table&#x000a0;<xref rid="jah32531-sup-0001" ref-type="supplementary-material">S2</xref>. Noncardiovascular death was most often caused by malignancy in both groups of patients.</p><p>For patients with UA/NSTEMI, the cumulative incidence of cardiovascular death remained higher than noncardiovascular death over the entirety of the 7&#x02010;year follow&#x02010;up; however, for patients with STEMI, noncardiovascular deaths outnumbered cardiovascular deaths after &#x0223c;4&#x000a0;years of follow&#x02010;up (Figure&#x000a0;<xref rid="jah32531-fig-0001" ref-type="fig">1</xref>). Patients with STEMI had a greater hazard of cardiovascular death compared with patients with UA/NSTEMI for 1&#x000a0;month, after which patients with UA/NSTEMI had a greater hazard of cardiovascular death (Figure&#x000a0;<xref rid="jah32531-fig-0002" ref-type="fig">2</xref>). Patients with STEMI had a smaller risk of noncardiovascular death than patients with UA/NSTEMI throughout the entirety of follow&#x02010;up (hazard ratio 0.73, 95% CI, 0.63&#x02013;0.84). Hazard ratios for patients with STEMI compared with UA/NSTEMI were significantly different for cardiovascular and noncardiovascular death over 7&#x000a0;years of follow&#x02010;up (<italic>P</italic>=0.02). For both STEMI and UA/NSTEMI patients, the cumulative incidence of the primary composite outcome was greater than that of noncardiovascular death alone over the entirety of follow&#x02010;up (Figure&#x000a0;<xref rid="jah32531-sup-0001" ref-type="supplementary-material">S1</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jah32531-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Cumulative incidence of cardiovascular and noncardiovascular death for patients with (A) <styled-content style="fixed-case">STEMI</styled-content> and (B) <styled-content style="fixed-case">UA</styled-content>/<styled-content style="fixed-case">NSTEMI</styled-content>. Seven&#x02010;year Kaplan&#x02013;Meier mortality rates: cardiovascular death: <styled-content style="fixed-case">STEMI</styled-content>, 4.5%; <styled-content style="fixed-case">UA</styled-content>/<styled-content style="fixed-case">NSTEMI</styled-content>, 6.5%; noncardiovascular death: <styled-content style="fixed-case">STEMI</styled-content>, 5.3%; <styled-content style="fixed-case">UA</styled-content>/<styled-content style="fixed-case">NSTEMI</styled-content>, 5.6%. <styled-content style="fixed-case">CV</styled-content> indicates cardiovascular; <styled-content style="fixed-case">NSTEMI</styled-content>, non&#x02010;<styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation myocardial infarction; <styled-content style="fixed-case">STEMI</styled-content>,<styled-content style="fixed-case"> ST</styled-content>&#x02010;segment elevation myocardial infarction; <styled-content style="fixed-case">UA</styled-content>, unstable angina.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-6-e005840-g001"/></fig><fig fig-type="Figure" xml:lang="en" id="jah32531-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Hazard ratio (<styled-content style="fixed-case">HR</styled-content>) for death over time for <styled-content style="fixed-case">STEMI</styled-content> compared with <styled-content style="fixed-case">UA</styled-content>/<styled-content style="fixed-case">NSTEMI</styled-content>. <styled-content style="fixed-case">HR</styled-content> curves are truncated at 6&#x000a0;months, but <styled-content style="fixed-case">HR</styled-content>s for cardiovascular and noncardiovascular death remained constant through the end of follow&#x02010;up. Solid lines represent <styled-content style="fixed-case">HR</styled-content> curves; dashed lines represent 95% confidence limits with confidence interval denoted by shading. <styled-content style="fixed-case">CV</styled-content> indicates cardiovascular; <styled-content style="fixed-case">NSTEMI</styled-content>, non&#x02010;<styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation myocardial infarction; <styled-content style="fixed-case">STEMI</styled-content>,<styled-content style="fixed-case"> ST</styled-content>&#x02010;segment elevation myocardial infarction; <styled-content style="fixed-case">UA</styled-content>, unstable angina.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-6-e005840-g002"/></fig><p>In a sensitivity analysis performed to account for the fact that IMPROVE&#x02010;IT's inclusion criteria limited enrollment of patients with UA to those with more severe atherosclerotic disease or diabetes mellitus, we repeated the above analyses for patients &#x02265;50&#x000a0;years old with either STEMI or NSTEMI as their qualifying diagnosis. Patients with these qualifying diagnoses were included in the trial regardless of the presence or absence of other risk factors. Overall, the results were similar to the primary analysis; patients with NSTEMI had a higher cumulative incidence of cardiovascular death than noncardiovascular death over the entirety of follow&#x02010;up, whereas noncardiovascular deaths predominated in patients with STEMI after the first 4&#x000a0;years of follow&#x02010;up (Figure&#x000a0;<xref rid="jah32531-sup-0001" ref-type="supplementary-material">S2</xref>). Similarly, patients with STEMI were more likely to die of cardiovascular causes over the first month of follow&#x02010;up, after which point patients with NSTEMI were more likely to die of cardiovascular causes, and patients with NSTEMI were more likely than patients with STEMI to die of noncardiovascular causes for the duration of follow&#x02010;up (Figure&#x000a0;<xref rid="jah32531-sup-0001" ref-type="supplementary-material">S3</xref>).</p><p>In a second sensitivity analysis that accounted for the different lengths of follow&#x02010;up for STEMI and UA/NSTEMI patients, we limited our population to patients enrolled while the trial was enrolling both categories of patients, with findings again similar to the primary analysis (Figure&#x000a0;<xref rid="jah32531-sup-0001" ref-type="supplementary-material">S4</xref>).</p></sec><sec id="jah32531-sec-0015"><title>Cumulative Incidence of Cardiovascular Versus Noncardiovascular Death By Age and Sex</title><p>Among patients &#x0003c;65&#x000a0;years old, 350 patients (7&#x02010;year cumulative incidence 3.8%, 95% CI, 3.4&#x02013;4.3%) died of cardiovascular causes over 7&#x000a0;years of follow&#x02010;up, compared with 321 (3.5%, 95% CI, 3.1&#x02013;4.0%) who died of noncardiovascular causes. In patients &#x02265;65&#x000a0;years old, 725 patients (10.3%, 95% CI, 9.5&#x02013;11.0%) died of cardiovascular causes over 7&#x02010;year follow&#x02010;up, and 685 (10.0%, 95% CI, 9.3&#x02013;10.8%) died of noncardiovascular causes. In both groups, the most common cause of cardiovascular death was death attributable to coronary heart disease and the most common cause of noncardiovascular death was malignancy (Table&#x000a0;<xref rid="jah32531-sup-0001" ref-type="supplementary-material">S1</xref>). Both patients &#x0003c;65 and those &#x02265;65&#x000a0;years old had a higher cumulative incidence of cardiovascular compared with noncardiovascular death over the entirety of follow&#x02010;up (Figure&#x000a0;<xref rid="jah32531-fig-0003" ref-type="fig">3</xref>). Compared with patients &#x0003c;65&#x000a0;years old, patients &#x02265;65 years old were roughly 3&#x02010;fold more likely than patients &#x0003c;65 years old to die because of either cardiovascular (hazard ratio 2.89; 95% CI, 2.54&#x02013;3.28) or noncardiovascular causes (hazard ratio 3.06; 95% CI, 2.68&#x02013;3.50) over the 7&#x02010;year follow&#x02010;up. Hazard ratios for patients &#x0003c;65 compared with those &#x02265;65&#x000a0;years old were not significantly different between cardiovascular and noncardiovascular death (<italic>P</italic>=0.53). For patients &#x0003c;65 years old and those &#x02265;65&#x000a0;years old, the cumulative incidence of the primary composite outcome was greater than that of noncardiovascular death alone over the entirety of follow&#x02010;up (Figure&#x000a0;<xref rid="jah32531-sup-0001" ref-type="supplementary-material">S5</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jah32531-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Cumulative incidence of cardiovascular and noncardiovascular death for patients (A) &#x0003c;65&#x000a0;years old and (B) &#x02265;65&#x000a0;years old. Seven&#x02010;year Kaplan&#x02013;Meier mortality rates: cardiovascular death: &#x0003c;65&#x000a0;years old, 3.4%; &#x02265;65, 9.1%; noncardiovascular death: &#x0003c;65, 3.2%; &#x02265;65, 8.6%). <styled-content style="fixed-case">CV</styled-content> indicates cardiovascular.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-6-e005840-g003"/></fig><p>Among male patients, 816 died of cardiovascular causes over 7&#x000a0;years of follow&#x02010;up (7&#x02010;year cumulative incidence 6.6%, 95% CI, 6.2&#x02013;7.1%), compared with 759 (6.3%, 95% CI, 5.8&#x02013;6.7%) who died of noncardiovascular causes. Among female patients, 259 (6.6%, 95% CI, 5.8&#x02013;7.4%) died of cardiovascular causes over the 7&#x02010;year follow&#x02010;up and 247 (6.5%, 95% CI, 5.7&#x02013;7.4%) died of noncardiovascular causes. In both groups, the most common cause of cardiovascular death was death caused by coronary heart disease, and the most common specific cause of noncardiovascular death was malignancy (Table&#x000a0;<xref rid="jah32531-sup-0001" ref-type="supplementary-material">S2</xref>). Male patients had a higher cumulative incidence of cardiovascular death than noncardiovascular death over the entirety of follow&#x02010;up; whereas among female patients, the cumulative incidence of noncardiovascular death equaled that of cardiovascular death after 6&#x000a0;years of follow&#x02010;up (Figure&#x000a0;<xref rid="jah32531-sup-0001" ref-type="supplementary-material">S6</xref>).</p></sec></sec><sec id="jah32531-sec-0016"><title>Discussion</title><p>In this analysis of IMPROVE&#x02010;IT, we demonstrate that, among patients stabilized after ACS, the relative contributions of cardiovascular and noncardiovascular death to overall mortality over long&#x02010;term follow&#x02010;up differ by type of presenting diagnosis. Although older patients were 3&#x02010;fold more likely than younger patients to die of either cardiovascular or noncardiovascular causes over the duration of follow&#x02010;up, the relative contributions of cardiovascular and noncardiovascular death were not affected by age. Similarly, both men and women were more likely to die of cardiovascular causes over the entirety of follow&#x02010;up. By contrast, patients with UA/NSTEMI were more likely to die of cardiovascular versus noncardiovascular causes for the entirety of follow&#x02010;up; however, in patients with STEMI, cardiovascular death was more common than noncardiovascular death only for &#x0223c;4&#x000a0;years, after which noncardiovascular death predominated. The sensitivity analyses suggest that the larger contribution of cardiovascular death to mortality in patients with NSTEMI was not because of trial inclusion parameters or differential follow&#x02010;up length specific to IMPROVE&#x02010;IT, but rather because of patient factors.</p><p>In IMPROVE&#x02010;IT, patients presenting with STEMI had higher mortality than those presenting with UA/NSTEMI for the first month, after which mortality rates in those with UA/NSTEMI were higher. This crossover is similar to what has been shown elsewhere, where patients with STEMI have higher in&#x02010;hospital and short&#x02010;term all&#x02010;cause mortality rates than those with UA/NSTEMI; but over longer&#x02010;term follow&#x02010;up, cumulative mortality for patients with UA/NSTEMI catches up with or surpasses that of STEMI patients.<xref rid="jah32531-bib-0008" ref-type="ref">8</xref>, <xref rid="jah32531-bib-0009" ref-type="ref">9</xref>, <xref rid="jah32531-bib-0013" ref-type="ref">13</xref>, <xref rid="jah32531-bib-0023" ref-type="ref">23</xref>, <xref rid="jah32531-bib-0024" ref-type="ref">24</xref> Our finding of that crossover occurring within 1&#x000a0;month is earlier than has been shown in other studies, and likely reflects the enrollment criteria of stabilization required before randomization. Long&#x02010;term higher cardiovascular and noncardiovascular mortality among UA/NSTEMI patients has been attributed to a higher baseline prevalence of multiple comorbidities, including multivessel coronary artery disease, heart failure, diabetes mellitus, chronic kidney disease, and chronic lung disease, a finding we also demonstrated in patients in IMPROVE&#x02010;IT.<xref rid="jah32531-bib-0001" ref-type="ref">1</xref>, <xref rid="jah32531-bib-0002" ref-type="ref">2</xref>, <xref rid="jah32531-bib-0005" ref-type="ref">5</xref>, <xref rid="jah32531-bib-0007" ref-type="ref">7</xref>, <xref rid="jah32531-bib-0009" ref-type="ref">9</xref>, <xref rid="jah32531-bib-0010" ref-type="ref">10</xref> Thus, it is important for clinicians and patients to understand that patients with UA/NSTEMI remain at higher risk for cardiovascular than noncardiovascular death over long&#x02010;term follow&#x02010;up, and that care of their multiple comorbidities should be targeted appropriately. Moreover, despite numerous pharmacologic, interventional, and surgical improvements, long&#x02010;term cardiovascular mortality following NSTEMI remains high.</p><p>In IMPROVE&#x02010;IT, patients with UA/NSTEMI had a higher cumulative incidence of cardiovascular death than noncardiovascular death throughout the follow&#x02010;up period. By contrast, for patients with STEMI, the cumulative incidence of cardiovascular death was higher than noncardiovascular death for the first 4&#x000a0;years, after which noncardiovascular death predominated. These findings are similar to those seen in an analysis of a registry of Japanese patients undergoing primary PCI: when patients with death within 6&#x000a0;months after PCI were excluded, the cumulative incidence of noncardiovascular death was greater than that of cardiovascular death after 2 to 3&#x000a0;years.<xref rid="jah32531-bib-0025" ref-type="ref">25</xref> We demonstrated, through our sensitivity analyses, that the likeliest explanation for these findings is that UA/NSTEMI patients' cardiovascular comorbidities were more extensive than those of STEMI patients, and continued to outweigh noncardiovascular comorbidities throughout follow&#x02010;up. The sensitivity analysis limited to patients enrolled while the trial was enrolling both STEMI and UA/NSTEMI patients was similar to the primary analysis, suggesting that differential follow&#x02010;up does not explain our findings. The second sensitivity analysis, limited to patients with positive cardiac biomarkers, controlled for differences in enrollment criteria between the STEMI and UA/NSTEMI cohorts of IMPROVE&#x02010;IT. IMPROVE&#x02010;IT limited enrollment of patients with UA/NSTEMI to those with positive cardiac biomarkers (ie, patients with NSTEMI) or UA with comorbidities that increase the likelihood of cardiovascular death.<xref rid="jah32531-bib-0026" ref-type="ref">26</xref>, <xref rid="jah32531-bib-0027" ref-type="ref">27</xref>, <xref rid="jah32531-bib-0028" ref-type="ref">28</xref> This analysis was also similar to the primary analysis, suggesting that IMPROVE&#x02010;IT's differential inclusion criteria did not drive our results. Thus, the relative impact of noncardiovascular death on event rates will vary both over time and by presenting diagnosis. Although death rates were higher in older adults, there was no difference in the relative incidence of cardiovascular compared with noncardiovascular death in older and younger adults.</p><p>Understanding the relative incidence of cardiovascular and noncardiovascular death has important implications for clinical trial design. Most clinical trials in cardiovascular disease utilize Kaplan&#x02013;Meier or Cox proportional hazards analyses to compare rates of composite end points, usually including cardiovascular mortality, between treatment arms.<xref rid="jah32531-bib-0020" ref-type="ref">20</xref>, <xref rid="jah32531-bib-0029" ref-type="ref">29</xref>, <xref rid="jah32531-bib-0030" ref-type="ref">30</xref> Noncardiovascular death acts as a competing risk, as patients who die are unable to subsequently experience a cardiovascular end point. Assuming that neither treatment arm has an effect on noncardiovascular mortality, failure to account for noncardiovascular death is unlikely to affect the point estimate for the treatment effect.<xref rid="jah32531-bib-0031" ref-type="ref">31</xref>, <xref rid="jah32531-bib-0032" ref-type="ref">32</xref> However, whether using traditional or a competing events framework, noncardiovascular deaths will reduce statistical power to identify a difference between groups as patients experiencing noncardiovascular death are censored at the time of death. This requires the recruitment of more patients or longer&#x02010;term follow&#x02010;up to accrue sufficient events. For trials that use all&#x02010;cause mortality as an end point, a treatment targeted to a cardiovascular pathway should have no effect on noncardiovascular death, and noncardiovascular deaths will not add to the power to identify a difference between groups. Indeed, if 1 group has a lower proportion of cardiovascular deaths than a comparator because of treatment efficacy, but a higher proportion of noncardiovascular deaths by random chance, then using all&#x02010;cause mortality as a component of the primary end point may obscure the true treatment effect. Though we found that the cumulative incidence of composite primary outcome events remains substantially higher than that of noncardiovascular death over the entirety of follow&#x02010;up in all groups studied, our findings suggest that following patients with STEMI past 4&#x000a0;years may yield diminishing returns as noncardiovascular deaths accrue faster than cardiovascular deaths, but that patients with UA/NSTEMI will continue to accrue cardiovascular deaths faster than noncardiovascular deaths for at least 7&#x000a0;years after their initial event. By contrast, neither sex nor older age appeared to have any effect on the relative incidence of cardiovascular compared with noncardiovascular death, though patients &#x0003e;65 years old had a 3&#x02010;fold higher incidence of both cardiovascular and noncardiovascular mortality. Any statistical power lost from noncardiovascular death among patients &#x0003e;65&#x000a0;years old should be offset by a higher rate of cardiovascular death in this population.</p><sec id="jah32531-sec-0017"><title>Limitations</title><p>In sensitivity analysis, we did not find that our results were impacted by trial inclusion parameters or differential follow&#x02010;up length in different subgroups. However, patient populations that enroll in clinical trials are different from those that do not,<xref rid="jah32531-bib-0033" ref-type="ref">33</xref>, <xref rid="jah32531-bib-0034" ref-type="ref">34</xref> and our findings regarding the relative risk of cardiovascular and noncardiovascular death for patients enrolled in IMPROVE&#x02010;IT may not apply more generally to the broader population with ACS. Furthermore, IMPROVE&#x02010;IT enrolled patients following discharge after an index ACS presentation, and these stabilized patients are likely to differ substantially from the full population of patients admitted to the hospital with ACS. However, our results were broadly consistent with a similar analysis performed in a registry population, but mortality rates were lower.<xref rid="jah32531-bib-0025" ref-type="ref">25</xref> Regardless, our findings are applicable to the population of stabilized ACS patients likely to be enrolled in clinical trials, and thus provide important information to guide design of future clinical trials.</p></sec></sec><sec id="jah32531-sec-0018"><title>Conclusion</title><p>In this analysis of IMPROVE&#x02010;IT, we demonstrate that, among patients stabilized after ACS, the relative contribution of cardiovascular and noncardiovascular death to overall mortality varies depending on type of ACS presentation and duration elapsed since the index event, but not depending on age at presentation. Noncardiovascular death competes with cardiovascular outcomes, effectively reducing sample size. Efficient design of long&#x02010;term cardiovascular outcome trials requires that sample size and power calculations include careful consideration of the competing risks of cardiovascular and noncardiovascular deaths when determining the desired proportions of patients with STEMI versus UA/NSTEMI. Our analysis specifically informs these considerations, and thus should be valuable and informative for future post&#x02010;ACS clinical trial design.</p></sec><sec id="jah32531-sec-0019"><title>Sources of Funding</title><p>The IMPROVE&#x02010;IT trial was supported by Merck &#x00026; Co., Inc. Fanaroff is supported by NIH grant 5T32HL069749&#x02010;13 and American Heart Association grant 17FTF33661087. Navar is supported by NHLBI grant K01HL133416.</p></sec><sec id="jah32531-sec-0020"><title>Disclosures</title><p>Fanaroff reports research funding through DCRI from Gilead Sciences. Roe reports research support from AstraZeneca, Eli Lilly &#x00026; Co., Janssen Pharmaceuticals, Sanofi&#x02010;Aventis, Daiichi&#x02010;Sankyo, Familial Hypercholesterolemia Foundation, Ferring Pharmaceuticals; educational activities for Amgen and Bristol&#x02010;Myers Squibb; and consulting for Eli Lilly &#x00026; Co, Daiichi&#x02010;Sankyo, Elsevier Publishers, Boehringer&#x02010;Ingelheim, PriMed, Myokardia, AstraZeneca, Merck &#x00026; Co, and Amgen. Navar reports research support from Amgen, Regeneron and Sanofi; and consulting for Amgen and Sanofi. Giugliano reports executive committee membership for the FOURIER and EBBINGHAUS studies, supported by a research grant from Amgen; research grant support to the Brigham and Women's Hospital from Amgen and Merck; honoraria for CME lectures and/or consulting from Amgen, Daiichi&#x02010;Sankyo, and Merck; and honoraria for CME lectures and/or consulting from the American College of Cardiology, Bristol&#x02010;Myers Squibb, CVS Caremark, and Pfizer. Wiviott reports grant support from Merck and Sanofi&#x02010;Aventis; grant support and personal fees from AstraZeneca, Bristol&#x02010;Myers Squibb, Eisai, Arena, and Eli Lilly/Daiichi&#x02010;Sankyo; personal fees from Aegerion, Angelmed, Janssen, Xoma, ICON Clinical, and Boston Clinical Research Institute outside the submitted work. Tershakovec reports employment by &#x00026; ownership interest in Merck &#x00026; Co., Inc. Braunwald reports membership of the TIMI Study Group, which has received research grant support from Amgen, Bristol&#x02010;Myers Squibb, and Merck to conduct clinical trials related to lipid therapy; grant support from GlaxoSmithKline, Bristol&#x02010;Myers Squibb, Duke University, AstraZeneca, and Johnson &#x00026; Johnson; grant support and personal fees from Daiichi&#x02010;Sankyo and Sanofi Aventis; personal fees from The Medicines Company, Menarini International, Bayer, and Medscape; and other support from Novartis. Blazing reports research support from Merck &#x00026; Co and Sanofi&#x02010;Aventis; educational activities for Amgen, Inc. and AstraZeneca; and consulting for Amgen, AstraZeneca, Pfizer; Merck &#x00026; Co., Novartis Pharmaceutical Company, and Sanofi&#x02010;Aventis. Others: The remaining authors have nothing to disclose.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jah32531-sup-0001"><caption><p>
<bold>Table&#x000a0;S1.</bold> Baseline Characteristics by Sex</p><p>
<bold>Table&#x000a0;S2.</bold> Causes of Death for Patients With STEMI, UA/NSTEMI, &#x0003c;65&#x000a0;y old, &#x02265;65&#x000a0;y old, male, and female</p><p>
<bold>Figure&#x000a0;S1.</bold> Cumulative incidence of the primary composite outcome and noncardiovascular death for patients with (A) STEMI and (B) UA/NSTEMI.</p><p>
<bold>Figure&#x000a0;S2.</bold> Cumulative incidence of cardiovascular and noncardiovascular death for patients &#x0003e;50&#x000a0;y old with (A) STEMI and (B) NSTEMI.</p><p>
<bold>Figure&#x000a0;S3.</bold> Hazard ratio for death over time for STEMI compared with NSTEMI among patients &#x0003e;50&#x000a0;y old.</p><p>
<bold>Figure&#x000a0;S4.</bold> Cumulative incidence of cardiovascular and noncardiovascular death for patients with (A) STEMI and (B) UA/NSTEMI enrolled before April 1, 2008.</p><p>
<bold>Figure&#x000a0;S5.</bold> Cumulative incidence of the primary composite outcome and noncardiovascular death for patients who were (A) &#x0003c;65&#x000a0;y old and (B) &#x02265;65&#x000a0;y old.</p><p>
<bold>Figure&#x000a0;S6.</bold> Cumulative incidence of cardiovascular and noncardiovascular death for (A) male and (B) female patients.</p></caption><media xlink:href="JAH3-6-e005840-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="jah32531-bibl-0001"><title>References</title><ref id="jah32531-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah32531-cit-0001">
<string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Gore</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Eagle</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Flather</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Sadiq</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kasper</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Rushton&#x02010;Mellor</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>FA</given-names>
</string-name>. <article-title>Baseline characteristics, management practices, and in&#x02010;hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)</article-title>. <source>Am J Cardiol</source>. <year>2002</year>;<volume>90</volume>:<fpage>358</fpage>&#x02013;<lpage>363</lpage>.<pub-id pub-id-type="pmid">12161222</pub-id></mixed-citation></ref><ref id="jah32531-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah32531-cit-0002">
<string-name>
<surname>Enriquez</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>de Lemos</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Parikh</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Spertus</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Holper</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Roe</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Rohatgi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Das</surname>
<given-names>SR</given-names>
</string-name>. <article-title>Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction</article-title>. <source>Am Heart J</source>. <year>2013</year>;<volume>165</volume>:<fpage>43</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">23237132</pub-id></mixed-citation></ref><ref id="jah32531-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah32531-cit-0003">
<string-name>
<surname>Montalescot</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Dallongeville</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Van Belle</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rouanet</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Baulac</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Degrandsart</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vicaut</surname>
<given-names>E</given-names>
</string-name>. <article-title>STEMI and NSTEMI: are they so different? 1&#x000a0;year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry)</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>:<fpage>1409</fpage>&#x02013;<lpage>1417</lpage>.<pub-id pub-id-type="pmid">17412730</pub-id></mixed-citation></ref><ref id="jah32531-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah32531-cit-0004">
<string-name>
<surname>Shroff</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Frederick</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Herzog</surname>
<given-names>CA</given-names>
</string-name>. <article-title>Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction</article-title>. <source>Am Heart J</source>. <year>2012</year>;<volume>163</volume>:<fpage>399</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">22424010</pub-id></mixed-citation></ref><ref id="jah32531-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah32531-cit-0005">
<string-name>
<surname>Fox</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Muntner</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>AY</given-names>
</string-name>, <string-name>
<surname>Alexander</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Roe</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Saucedo</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Kontos</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</string-name>. <article-title>Use of evidence&#x02010;based therapies in short&#x02010;term outcomes of ST&#x02010;segment elevation myocardial infarction and non&#x02010;ST&#x02010;segment elevation myocardial infarction in patients with chronic kidney disease a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network Registry</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>121</volume>:<fpage>357</fpage>&#x02013;<lpage>365</lpage>.<pub-id pub-id-type="pmid">20065168</pub-id></mixed-citation></ref><ref id="jah32531-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah32531-cit-0006">
<string-name>
<surname>Garc&#x000ed;a&#x02010;Garc&#x000ed;a</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Subirana</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Sala</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bruguera</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sanz</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Valle</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Ar&#x000f3;s</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Fiol</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Molina</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Serra</surname>
<given-names>J</given-names>
</string-name>. <article-title>Long&#x02010;term prognosis of first myocardial infarction according to the electrocardiographic pattern (ST elevation myocardial infarction, non&#x02010;ST elevation myocardial infarction and non&#x02010;classified myocardial infarction) and revascularization procedures</article-title>. <source>Am J Cardiol</source>. <year>2011</year>;<volume>108</volume>:<fpage>1061</fpage>&#x02013;<lpage>1067</lpage>.<pub-id pub-id-type="pmid">21791326</pub-id></mixed-citation></ref><ref id="jah32531-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah32531-cit-0007">
<string-name>
<surname>Polonski</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gasior</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gierlotka</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Osadnik</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kalarus</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Trusz&#x02010;Gluza</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zembala</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wilczek</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lekston</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zdrojewski</surname>
<given-names>T</given-names>
</string-name>. <article-title>A comparison of ST elevation versus non&#x02010;ST elevation myocardial infarction outcomes in a large registry database: are non&#x02010;ST myocardial infarctions associated with worse long&#x02010;term prognoses?</article-title>
<source>Int J Cardiol</source>. <year>2011</year>;<volume>152</volume>:<fpage>70</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">20684999</pub-id></mixed-citation></ref><ref id="jah32531-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah32531-cit-0008">
<string-name>
<surname>Chan</surname>
<given-names>MY</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Newby</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Kong</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Roe</surname>
<given-names>MT</given-names>
</string-name>. <article-title>Long&#x02010;term mortality of patients undergoing cardiac catheterization for ST&#x02010;elevation and non&#x02010;ST&#x02010;elevation myocardial infarction</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>119</volume>:<fpage>3110</fpage>&#x02013;<lpage>3117</lpage>.<pub-id pub-id-type="pmid">19506116</pub-id></mixed-citation></ref><ref id="jah32531-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah32531-cit-0009">
<string-name>
<surname>Abbott</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>
<given-names>HN</given-names>
</string-name>, <string-name>
<surname>Vlachos</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Selzer</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>DO</given-names>
</string-name>. <article-title>Comparison of outcome in patients with ST&#x02010;elevation versus non&#x02010;ST&#x02010;elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry)</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>100</volume>:<fpage>190</fpage>&#x02013;<lpage>195</lpage>.<pub-id pub-id-type="pmid">17631068</pub-id></mixed-citation></ref><ref id="jah32531-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah32531-cit-0010">
<string-name>
<surname>Allen</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>O'Donnell</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Camargo</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Giugliano</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Lloyd&#x02010;Jones</surname>
<given-names>DM</given-names>
</string-name>. <article-title>Comparison of long&#x02010;term mortality across the spectrum of acute coronary syndromes</article-title>. <source>Am Heart J</source>. <year>2006</year>;<volume>151</volume>:<fpage>1065</fpage>&#x02013;<lpage>1071</lpage>.<pub-id pub-id-type="pmid">16644337</pub-id></mixed-citation></ref><ref id="jah32531-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah32531-cit-0011">
<string-name>
<surname>Terkelsen</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Lassen</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>N&#x000f8;rgaard</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Gerdes</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>G&#x000f8;tzsche</surname>
<given-names>LBH</given-names>
</string-name>, <string-name>
<surname>Nielsen</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>HR</given-names>
</string-name>. <article-title>Mortality rates in patients with ST&#x02010;elevation vs. non&#x02010;ST&#x02010;elevation acute myocardial infarction: observations from an unselected cohort</article-title>. <source>Eur Heart J</source>. <year>2005</year>;<volume>26</volume>:<fpage>18</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">15615795</pub-id></mixed-citation></ref><ref id="jah32531-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah32531-cit-0012">
<string-name>
<surname>Agarwal</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Singla</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Hreybe</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Saba</surname>
<given-names>S</given-names>
</string-name>. <article-title>Clinical predictors of late death in survivors of acute myocardial infarction</article-title>. <source>Tex Heart Inst J</source>. <year>2009</year>;<volume>36</volume>:<fpage>24</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">19436782</pub-id></mixed-citation></ref><ref id="jah32531-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah32531-cit-0013">
<string-name>
<surname>Vora</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>TY</given-names>
</string-name>, <string-name>
<surname>Hellkamp</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Goyal</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Roe</surname>
<given-names>MT</given-names>
</string-name>. <article-title>Differences in short&#x02010;and long&#x02010;term outcomes among older patients with ST&#x02010;elevation verses non&#x02010;ST&#x02010;elevation myocardial infarction with angiographically proven coronary artery disease</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2016</year>;<volume>9</volume>:<fpage>513</fpage>&#x02013;<lpage>522</lpage>.<pub-id pub-id-type="pmid">27601458</pub-id></mixed-citation></ref><ref id="jah32531-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah32531-cit-0014">
<string-name>
<surname>Cox</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Stone</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>Grines</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Stuckey</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Zimetbaum</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Tcheng</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Turco</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Guagliumi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Iwaoka</surname>
<given-names>RS</given-names>
</string-name>. <article-title>Comparative early and late outcomes after primary percutaneous coronary intervention in ST&#x02010;segment elevation and non&#x02010;ST&#x02010;segment elevation acute myocardial infarction (from the CADILLAC trial)</article-title>. <source>Am J Cardiol</source>. <year>2006</year>;<volume>98</volume>:<fpage>331</fpage>&#x02013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">16860018</pub-id></mixed-citation></ref><ref id="jah32531-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah32531-cit-0015">
<string-name>
<surname>Aguirre</surname>
<given-names>FV</given-names>
</string-name>, <string-name>
<surname>Younis</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Chaitman</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>McMahon</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Kern</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Sopko</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Rogers</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>L</given-names>
</string-name>. <article-title>Early and 1&#x02010;year clinical outcome of patients' evolving non&#x02010;Q&#x02010;wave versus Q&#x02010;wave myocardial infarction after thrombolysis results from the TIMI II study</article-title>. <source>Circulation</source>. <year>1995</year>;<volume>91</volume>:<fpage>2541</fpage>&#x02013;<lpage>2548</lpage>.<pub-id pub-id-type="pmid">7743615</pub-id></mixed-citation></ref><ref id="jah32531-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah32531-cit-0016">
<string-name>
<surname>Goodman</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Langer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Wildermann</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>Barbagelata</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sgarbossa</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Wagner</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Topol</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Non&#x02010;Q&#x02010;wave versus Q&#x02010;wave myocardial infarction after thrombolytic therapy angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries&#x02010;I angiographic substudy</article-title>. <source>Circulation</source>. <year>1998</year>;<volume>97</volume>:<fpage>444</fpage>&#x02013;<lpage>450</lpage>.<pub-id pub-id-type="pmid">9490238</pub-id></mixed-citation></ref><ref id="jah32531-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah32531-cit-0017">
<string-name>
<surname>Maki</surname>
<given-names>E</given-names>
</string-name>. <article-title>Power and sample size considerations in clinical trials with competing risk endpoints</article-title>. <source>Pharm Stat</source>. <year>2006</year>;<volume>5</volume>:<fpage>159</fpage>&#x02013;<lpage>171</lpage>.<pub-id pub-id-type="pmid">17080750</pub-id></mixed-citation></ref><ref id="jah32531-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah32531-cit-0018">
<string-name>
<surname>Berry</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Ngo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Samelson</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Kiel</surname>
<given-names>DP</given-names>
</string-name>. <article-title>Competing risk of death: an important consideration in studies of older adults</article-title>. <source>J Am Geriatr Soc</source>. <year>2010</year>;<volume>58</volume>:<fpage>783</fpage>&#x02013;<lpage>787</lpage>.<pub-id pub-id-type="pmid">20345862</pub-id></mixed-citation></ref><ref id="jah32531-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah32531-cit-0019">
<string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Giugliano</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Blazing</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Sisk</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Strony</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Musliner</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>McCabe</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Veltri</surname>
<given-names>E</given-names>
</string-name>. <article-title>Rationale and design of IMPROVE&#x02010;IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes</article-title>. <source>Am Heart J</source>. <year>2008</year>;<volume>156</volume>:<fpage>826</fpage>&#x02013;<lpage>832</lpage>.<pub-id pub-id-type="pmid">19061694</pub-id></mixed-citation></ref><ref id="jah32531-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah32531-cit-0020">
<string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Blazing</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Giugliano</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>McCagg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Theroux</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Darius</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Ophuis</surname>
<given-names>TO</given-names>
</string-name>, <string-name>
<surname>Jukema</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Ezetimibe added to statin therapy after acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>:<fpage>2387</fpage>&#x02013;<lpage>2397</lpage>.<pub-id pub-id-type="pmid">26039521</pub-id></mixed-citation></ref><ref id="jah32531-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah32531-cit-0021">
<string-name>
<surname>Blazing</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Giugliano</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Musliner</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Tershakovec</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Reist</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>McCagg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18&#x000a0;144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE&#x02010;IT study population</article-title>. <source>Am Heart J</source>. <year>2014</year>;<volume>168</volume>:<fpage>205</fpage>&#x02013;<lpage>212</lpage>.e1.<pub-id pub-id-type="pmid">25066560</pub-id></mixed-citation></ref><ref id="jah32531-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah32531-cit-0022">
<string-name>
<surname>Lunn</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McNeil</surname>
<given-names>D</given-names>
</string-name>. <article-title>Applying Cox regression to competing risks</article-title>. <source>Biometrics</source>. <year>1995</year>;<volume>51</volume>:<fpage>524</fpage>&#x02013;<lpage>532</lpage>.<pub-id pub-id-type="pmid">7662841</pub-id></mixed-citation></ref><ref id="jah32531-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah32531-cit-0023">
<string-name>
<surname>Armstrong</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>Topol</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Betriu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Van de Werf</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Acute coronary syndromes in the GUSTO&#x02010;IIb trial: prognostic insights and impact of recurrent ischemia</article-title>. <source>Circulation</source>. <year>1998</year>;<volume>98</volume>:<fpage>1860</fpage>&#x02013;<lpage>1868</lpage>.<pub-id pub-id-type="pmid">9799205</pub-id></mixed-citation></ref><ref id="jah32531-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah32531-cit-0024">
<string-name>
<surname>Yan</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fitchett</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Chow</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Fowlis</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>McAvinue</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Roe</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Tu</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Langer</surname>
<given-names>A</given-names>
</string-name>. <article-title>One&#x02010;year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry)</article-title>. <source>Am J Cardiol</source>. <year>2004</year>;<volume>94</volume>:<fpage>25</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">15219503</pub-id></mixed-citation></ref><ref id="jah32531-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah32531-cit-0025">
<string-name>
<surname>Yamashita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shiomi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Morimoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yaku</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Furukawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ando</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kadota</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nagao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shizuta</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ono</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>
<given-names>T</given-names>
</string-name>; <collab collab-type="authors">CREDO&#x02010;Kyoto AMI Registry Investigators</collab>
. <article-title>Cardiac and noncardiac causes of long&#x02010;term mortality in ST&#x02010;segment&#x02010;elevation acute myocardial infarction patients who underwent primary percutaneous coronary intervention</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2017</year>;<volume>10</volume>: <fpage>e002790</fpage>.<pub-id pub-id-type="pmid">28073848</pub-id></mixed-citation></ref><ref id="jah32531-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah32531-cit-0026">
<string-name>
<surname>Criqui</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Langer</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Fronek</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Feigelson</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Klauber</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>McCann</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Browner</surname>
<given-names>D</given-names>
</string-name>. <article-title>Mortality over a period of 10&#x000a0;years in patients with peripheral arterial disease</article-title>. <source>N Engl J Med</source>. <year>1992</year>;<volume>326</volume>:<fpage>381</fpage>&#x02013;<lpage>386</lpage>.<pub-id pub-id-type="pmid">1729621</pub-id></mixed-citation></ref><ref id="jah32531-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah32531-cit-0027">
<string-name>
<surname>Beckman</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Creager</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Libby</surname>
<given-names>P</given-names>
</string-name>. <article-title>Diabetes and atherosclerosis: epidemiology, pathophysiology, and management</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>287</volume>:<fpage>2570</fpage>&#x02013;<lpage>2581</lpage>.<pub-id pub-id-type="pmid">12020339</pub-id></mixed-citation></ref><ref id="jah32531-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah32531-cit-0028">
<string-name>
<surname>Califf</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Carver</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>D'agostino</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Strauss</surname>
<given-names>W</given-names>
</string-name>. <article-title>27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management</article-title>. <source>J Am Coll Cardiol</source>. <year>1996</year>;<volume>27</volume>:<fpage>1007</fpage>&#x02013;<lpage>1019</lpage>.<pub-id pub-id-type="pmid">8609316</pub-id></mixed-citation></ref><ref id="jah32531-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah32531-cit-0029">
<string-name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>McCabe</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Montalescot</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ruzyllo</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Gottlieb</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Neumann</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Ardissino</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>De Servi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Riesmeyer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Weerakkody</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Antman</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Prasugrel versus clopidogrel in patients with acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>:<fpage>2001</fpage>&#x02013;<lpage>2015</lpage>.<pub-id pub-id-type="pmid">17982182</pub-id></mixed-citation></ref><ref id="jah32531-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah32531-cit-0030">
<string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Budaj</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Emanuelsson</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Held</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Horrow</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Husted</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Katus</surname>
<given-names>H</given-names>
</string-name>. <article-title>Ticagrelor versus clopidogrel in patients with acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>:<fpage>1045</fpage>&#x02013;<lpage>1057</lpage>.<pub-id pub-id-type="pmid">19717846</pub-id></mixed-citation></ref><ref id="jah32531-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah32531-cit-0031">
<string-name>
<surname>Prentice</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Kalbfleisch</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>AV</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Flournoy</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Farewell</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Breslow</surname>
<given-names>N</given-names>
</string-name>. <article-title>The analysis of failure times in the presence of competing risks</article-title>. <source>Biometrics</source>. <year>1978</year>;<volume>34</volume>:<fpage>541</fpage>&#x02013;<lpage>554</lpage>.<pub-id pub-id-type="pmid">373811</pub-id></mixed-citation></ref><ref id="jah32531-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah32531-cit-0032">
<string-name>
<surname>Haneuse</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>KH</given-names>
</string-name>. <article-title>Semi&#x02010;competing risks data analysis accounting for death as a competing risk when the outcome of interest is nonterminal</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2016</year>;<volume>9</volume>:<fpage>322</fpage>&#x02013;<lpage>331</lpage>.<pub-id pub-id-type="pmid">27072677</pub-id></mixed-citation></ref><ref id="jah32531-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jah32531-cit-0033">
<string-name>
<surname>Martin</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Ou</surname>
<given-names>FS</given-names>
</string-name>, <string-name>
<surname>Newby</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Sutton</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Felker</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>TY</given-names>
</string-name>. <article-title>Patient&#x02010;and trial&#x02010;specific barriers to participation in cardiovascular randomized clinical trials</article-title>. <source>J Am Coll Cardiol</source>. <year>2013</year>;<volume>61</volume>:<fpage>762</fpage>&#x02013;<lpage>769</lpage>.<pub-id pub-id-type="pmid">23410547</pub-id></mixed-citation></ref><ref id="jah32531-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah32531-cit-0034">
<string-name>
<surname>Hutchinson&#x02010;Jaffe</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Goodman</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>RT</given-names>
</string-name>, <string-name>
<surname>Wald</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Elbarouni</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rose</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Eagle</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Baer</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Langer</surname>
<given-names>A</given-names>
</string-name>. <article-title>Comparison of baseline characteristics, management and outcome of patients with non&#x02010;ST&#x02010;segment elevation acute coronary syndrome in versus not in clinical trials</article-title>. <source>Am J Cardiol</source>. <year>2010</year>;<volume>106</volume>:<fpage>1389</fpage>&#x02013;<lpage>1396</lpage>.<pub-id pub-id-type="pmid">21059426</pub-id></mixed-citation></ref></ref-list></back></article>